文献速递鼻科

鼻后神经射频神经毁损术的系统评价与Meta分析

Radiofrequency Neurolysis of the Posterior Nasal Nerve: A Systematic Review and Meta-Analysis.
PubMed 文献 · Laryngoscope · 2026-08-02

该系统评价与Meta分析纳入12项研究共924例成人慢性鼻炎患者,评估温度控制射频(TCRF)鼻后神经毁损术的疗效与安全性。结果显示TCRF在3个月至3年各随访 interval 均显著降低鼻症状总分(rTNSS),症状应答率从3个月的74%升至长期随访的81%-84%,生活质量持续改善,不良事件少见且轻微。

要点

  • TCRF鼻后神经毁损术在3个月至3年各时间点均显著降低rTNSS。
  • 症状应答率(改善≥30%)从3个月74%升至长期81%-84%。
  • 不良事件少见、轻微且短暂,生活质量改善持续至3年。

核心结论

  • TCRF鼻后神经毁损术对药物难治性慢性鼻炎患者提供安全、有临床意义且持续至3年的鼻症状和生活质量改善。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA 2020指南(PROSPERO: CRD420261345320),检索PubMed/MEDLINE、Embase和Cochrane Library从建库至2026年3月。
  • 纳入12项研究共924例接受TCRF鼻后神经毁损术的成人慢性鼻炎患者,采用随机效应模型在3个月、6个月、12个月、2年和3年合并结局。

主要发现

  • TCRF在3个月降低rTNSS -3.96(95%CI -4.26至-3.67),6个月-4.50(95%CI -4.91至-4.09),12个月-4.70(95%CI -5.04至-4.37)。
  • 2年降低rTNSS -5.06(95%CI -5.67至-4.44),3年-4.59(95%CI -5.00至-4.19)。
  • 症状应答率(改善≥30%)从3个月74%升至长期随访81%-84%。
  • Mini鼻结膜炎生活质量问卷评分持续改善至3年。
  • 不良事件少见、轻微且短暂。

关键数值与推荐

  • 症状应答定义为rTNSS改善≥30%。
  • 各随访时间点rTNSS较基线的变化值及95%CI见findings。

临床怎么用

  • 对于药物难治性慢性鼻炎成人患者,TCRF鼻后神经毁损术可作为微创治疗选择,疗效可持续至3年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Temperature-controlled radiofrequency (TCRF) neurolysis of the posterior nasal nerve is a minimally invasive treatment for chronic rhinitis. While early studies show short-term efficacy, long-term durability remains unclear. This study evaluated the short- and long-term efficacy and safety of TCRF neurolysis across discrete follow-up intervals. DATA SOURCES: PubMed/MEDLINE, Embase, and the Cochrane Library were searched from inception to March 2026. REVIEW METHODS: Following PRISMA 2020 guidelines (PROSPERO: CRD420261345320), studies evaluating adults undergoing TCRF neurolysis for chronic rhinitis with quantitative outcomes were included. Random-effects meta-analyses pooled outcomes at 3 months, 6 months, 12 months, 2 years, and 3 years. RESULTS: Twelve studies (924 patients) were included. TCRF neurolysis significantly reduced total nasal symptom scores (rTNSS) across all intervals: 3 months (-3.96, 95% CI -4.26 to -3.67), 6 months (-4.50, 95% CI -4.91 to -4.09), 12 months (-4.70, 95% CI -5.04 to -4.37), 2 years (-5.06, 95% CI -5.67 to -4.44), and 3 years (-4.59, 95% CI -5.00 to -4.19). Symptom responder rates (≥ 30% improvement) rose from 74% at 3 months to 81%-84% during long-term follow-up. Mini Rhinoconjunctivitis Quality of Life Questionnaire scores demonstrated sustained improvements up to 3 years. Adverse events were infrequent, minor, and transient. CONCLUSION: TCRF neurolysis provides safe, clinically meaningful, and durable improvements in nasal symptoms and quality of life for up to 3 years, offering a robust therapeutic option for medically refractory chronic rhinitis.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Jamileh E, Muhammad F, Xamza M, et al. Radiofrequency Neurolysis of the Posterior Nasal Nerve: A Systematic Review and Meta-Analysis. Laryngoscope. 2026. PMID: 42543684. doi:10.1002/lary.70763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。